Johnson & Johnson's ($JNJ) Janssen Biotech unit has made a big deal with the small biotech Pharmacyclics. Janssen will pay $150 million up front--and $975 million total, if milestones are met--for a midstage blood-cancer treatment. Report
USP <232> Elemental Impurities—Limits and <233> Elemental Impurities—Procedures are close to being adopted. But the monographs will not provide specific sample preparation methods. This article outlines three case studies for sample preparation. Download Today.
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!